Table 1 Clinical characteristics and SVR analysis of Taiwanese patients with chronic HCV infection

From: IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection

Clinical characteristic

Total (N=728)

SVR positive (N=559)

SVR negative (N=169)

P-value

Age on IFN therapy

51.2±10.4

50.1±10.5

54.8±9.3

<0.001*

 Male

444 (61.0%)

361 (64.6%)

83 (49.1%)

<0.001*

 Liver cirrhosis

246 (33.8%)

155 (27.7%)

91 (53.8%)

<0.001*

HCV genotype:

 Genotype 1

424 (58.2%)

281 (50.3%)

143 (84.6%)

<0.001*

 Non-genotype 1

304 (41.8%)

278 (49.7%)

26 (15.4%)

 

HCV RNA ≥0.4 miu

318 (43.7%)

204 (36.5%)

114 (67.5%)

<0.001*

BMI ≥27 kg m–2

146 (20.1%)

106 (19.0%)

40 (23.7%)

0.181

Adherence

483 (66.3%)

386 (69.1%)

39 (23.1%)

0.005*

Regimen

 INTRON+RBV

126 (17.3%)

98 (17.5%)

28 (16.6%)

0.772

 PEG-IFN+RBV

602 (82.7%)

461 (82.5%)

141 (83.4%)

 
  1. Abbreviations: BMI, body mass index; HCV, hepatitis C virus; PEG IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological response.
  2. *P<0.05.
Back to article page